<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadoteridol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadoteridol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadoteridol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8886" href="/d/html/8886.html" rel="external">see "Gadoteridol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11744" href="/d/html/11744.html" rel="external">see "Gadoteridol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708886"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic systemic fibrosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis in patients with impaired elimination of the drugs. Avoid use of gadolinium-based contrast agents in these patients unless the diagnostic information is essential and not available with noncontrast-enhanced magnetic resonance imaging (MRI) or other modalities. Nephrogenic systemic fibrosis may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. The risk for nephrogenic systemic fibrosis appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>), or acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:2em;">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing. For patients at highest risk for nephrogenic systemic fibrosis, do not exceed the recommended gadoteridol dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F175126"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Prohance</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867016"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Prohance</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1015798"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Radiological/Contrast Media, Nonionic</span></li></ul></div>
<div class="block don drugH1Div" id="F55592859"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800bae13-16dc-4a0e-adc3-edd65ef3b79d">CNS imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS imaging:</b> Term neonates: IV: 0.1 mmol/kg (0.2 mL/kg).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F3410028"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800bae13-16dc-4a0e-adc3-edd65ef3b79d">CNS imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS imaging:</b> Infants, Children, and Adolescents: IV: 0.1 mmol/kg (0.2 mL/kg).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112249"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment necessary; use with caution in patients with kidney impairment or at high risk; risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: There are no pediatric-specific recommendations; based on experience in adult patients, the following has been observed:</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Based on data in adult patients, peritoneal dialysis is likely to be less efficient at clearing gadolinium than hemodialysis (Joffe 1998; Kuo 2007).</p></div>
<div class="block dohp drugH1Div" id="F51112250"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F3410029"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8886" href="/d/html/8886.html" rel="external">see "Gadoteridol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800bae13-16dc-4a0e-adc3-edd65ef3b79d">CNS imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS imaging:</b>
<b>IV:</b> 0.1 mmol/kg (0.2 mL/kg); if needed, a second dose of 0.2 mmol/kg (0.4 mL/kg) may be repeated once within 30 minutes of the first dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f18640e0-22c5-4aed-9de9-395c5479987c">Extracranial/extraspinal head and neck imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extracranial/extraspinal head and neck imaging:</b>
<b>IV:</b> 0.1 mmol/kg (0.2 mL/kg).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991872"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary. Risk for nephrogenic systemic fibrosis development increases as renal function decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>
<div class="block doha drugH1Div" id="F50989185"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F3410010"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Nausea (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, chest tightness, cold extremity, facial edema, first degree atrioventricular block, flushing, hypotension, increased heart rate, palpitations, presyncope, syncope, vascular injury (rupture), vasodilation, vasospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis, morbilliform rash, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased blood urea nitrogen, hyperchloremia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, decreased appetite, diarrhea, dysgeusia, gingival pain, gingivitis, oral itching, swollen tongue, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (including erythema at injection site, sensation of cold, pain at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, dizziness, feeling hot, formication, headache, hypoesthesia, lethargy, loss of consciousness, mental status change, migraine, pain, paresthesia, seizure, taste disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, back pain, hypokinesia, muscle rigidity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pruritus, increased lacrimation</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ear sign and symptom (discomfort), tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dry throat, dyspnea, nasal discomfort, rhinitis, throat irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Nephrogenic systemic fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, hypertension, vasodepressor syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (including angioedema, bronchospasm, cyanosis, eyelid edema, pharyngeal edema), nonimmune anaphylaxis (including circulatory shock)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Coma</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F3410006"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to gadoteridol or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F3410007"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe and fatal hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions involving cardiovascular, cutaneous, and/or respiratory symptoms, have occurred. Patients with a history of allergic reactions, asthma, or other hypersensitivity-like disorders may be at increased risk. Closely observe patients during and for up to 2 hours after the procedure. If hypersensitivity reaction occurs, discontinue gadoteridol immediately and have appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) available during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with</b>
<b> impaired elimination of the drugs<b>; avoid use in these patients unless diagnostic information is essential</b></b>
<b>and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest in patients with acute kidney injury or chronic, severe renal disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>). Screen patients for acute kidney injury and other conditions that may reduce renal function; estimate GFR in patients at risk for chronically reduced renal function (eg, diabetes, hypertension, &gt;60 years). For patients at highest risk for NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration. </b>The risk for NSF appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of gadolinium agents, generally within 48 hours following administration. In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred; risk of acute kidney injury may increase with increasing dose; administer the lowest dose necessary. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: Physicians should be experienced with diagnostic procedures using contrast agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Repeat doses: Repeated procedures have not been studied; safety of sequential doses has only been studied in adults in central nervous system during the same diagnostic session.</p></div>
<div class="block dosfc drugH1Div" id="F27994112"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">ProHance prefilled syringe tip cap contains latex.</p></div>
<div class="block foc drugH1Div" id="F175121"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prohance: 279.3 mg/mL (5 mL, 10 mL, 15 mL, 17 mL [DSC], 20 mL, 50 mL)</p></div>
<div class="block geq drugH1Div" id="F175118"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323165"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Prohance Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">279.3 mg/mL (per mL): $6.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867017"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prohance: 279.3 mg/mL (5 mL, 10 mL)</p></div>
<div class="block admp drugH1Div" id="F52612901"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer as a rapid infusion (10 to 60 mL/minute) or as a bolus (&gt;60 mL/minute). Flush line with at least 5 mL NS to ensure complete injection of medium. Imaging should be completed within 60 minutes of injection.</p></div>
<div class="block adm drugH1Div" id="F3410032"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer as a rapid infusion (10 to 60 mL/minute) or as a bolus (&gt;60 mL/minute). Flush line with NS 5 mL to ensure complete injection of medium. Imaging should be completed within 60 minutes of injection.</p></div>
<div class="block sts drugH1Div" id="F3410019"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light. Do not freeze; if freezing occurs, bring to room temperature before use. If allowed to stand at room temperature for a minimum of 60 minutes, gadoteridol should return to a clear, colorless or slightly yellow solution. Before use, examine the product to ensure that all solids are redissolved, and that the container and closure have not been damaged.  If solids persist, discard the vial. Discard frozen syringes. Pharmacy bulk package vials should only be entered once and must be discarded within 8 hours after initial puncture; storage temperature should not exceed of 25°C (77°F) during this time frame. If drawn into a plastic disposable syringe for administration, use immediately after preparation.</p></div>
<div class="block meg drugH1Div" id="F51378208"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Prohance: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021489s014lbl.pdf%23page%3D16&amp;token=Pnic8sB%2B7aUosAgp7fpFzYTgA1ityKETBZGoldvITw0Hb46eSqbOQdYEbTtyfjyCZnSD1Oizxk88DxzkjlwoxD4Ygt4EUbZCxp8%2Fez0M0hyogmAsfXtmWM0r8RhmtINv&amp;TOPIC_ID=131052" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021489s014lbl.pdf#page=16</a></p></div>
<div class="block usep drugH1Div" id="F53567046"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">For use in MRI to visualize lesions with disrupted blood-brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine, and associated tissues (FDA approved in all ages); for use in MRI in adults to visualize lesions in the head and neck (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F13299380"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F5563034"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F175124"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Gadolinium-based contrast agents may cross the placenta (ACOG 2017; ACR 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients may be at increased risk for gadolinium retention. Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2020).</p></div>
<div class="block mopp drugH1Div" id="F53567037"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of hypersensitivity (during and for several hours after procedure); renal function (prior to administration and as clinically indicated); signs/symptoms of nephrogenic systemic fibrosis (during and following procedure).</p></div>
<div class="block pha drugH1Div" id="F3410020"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gadoteridol is a gadolinium-containing paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.</p></div>
<div class="block phk drugH1Div" id="F3410022"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 204 ± 58 mL/kg; distribution half-life: 0.2 ± 0.04 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.57 ± 0.08 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~94%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175125"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Prohance</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. doi:10.1097/AOG.0000000000002355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoteridol-pediatric-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. 2020. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed January 5, 2021.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control. Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri. <i>MMWR Weekly Rep</i>. 2007;56(07):137-141.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16431890">
<a name="16431890"></a>Grobner T. Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis. <i>Nephrol Dial Transplant</i>. 2006;21(4):1104-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoteridol-pediatric-drug-information/abstract-text/16431890/pubmed" id="16431890" target="_blank">16431890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653466">
<a name="9653466"></a>Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis. <i>Acad Radiol</i>. 1998;5(7):491-502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoteridol-pediatric-drug-information/abstract-text/9653466/pubmed" id="9653466" target="_blank">9653466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17213364">
<a name="17213364"></a>Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis. <i>Radiology</i>. 2007;242(3):647-649.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoteridol-pediatric-drug-information/abstract-text/17213364/pubmed" id="17213364" target="_blank">17213364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350296">
<a name="11350296"></a>Okada S, Katagiri K, Kumazaki T, et al. Safety of Gadolinium Contrast Agent in Hemodialysis Patients. <i> Acta Radiol</i>. 2001;42(3):339-341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadoteridol-pediatric-drug-information/abstract-text/11350296/pubmed" id="11350296" target="_blank">11350296</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  ProHance Multipack (gadoteridol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ProHance.2">
<a name="ProHance.2"></a>ProHance single dose (gadoteridol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Widmark JM. Imaging-related Medications: A Class Overview. <i>Proc(Bayl Univ Med Cent)</i>. 2007;20(4):408-417.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131052 Version 19.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
